Thursday, November 05, 2015

Gilead Sciences HIV Drug Wins FDA Approval; Genvoya Has Potential to Advance Long-Term Treatment of HIV

I'm not the most knowledgeable person in the world about HIV treatments, but this sounds pretty huge to me:

The Wall Street Journal reports:
Gilead Sciences said Thursday the U.S. Food and Drug Administration approved the biotech company’s single tablet regimen treatment for HIV-1 infection. Genvoya is the first drug with tenofovir alafenamide, or TAF, to receive FDA approval. Chief Executive John Martin said Genvoya is the first in a portfolio of TAF-based products that has the potential to advance the long-term treatment of HIV.

“While exceptional progress has been made in the field of HIV, there is still a need for new treatment options that may help improve the health of people as they grow older with the disease,” he said.

Dr. David Wohl, lead author of the Genvoya efficacy analysis, said that as the HIV patient population ages there is an increased risk for development of age- and treatment-related diseases, including low bone mineral density and renal impairment as a result of the combination of HIV infection, antiretroviral treatments and the natural aging process.
Genvoya is intended as a complete regimen for the treatment of HIV-1 infection in adults and children 12 years and older who have no antiretroviral treatment history or to replace a current antiretroviral regimen, according to Gilead.

No comments:

Share This

Blog Widget by LinkWithin